Cantor Fitzgerald Believes SUPN Still Has Room to Grow

By Ryan Adsit

In a report released yesterday, William Tanner from Cantor Fitzgerald reiterated a Buy rating on Supernus Pharmaceuticals (NASDAQ: SUPN), with a price target of $31. The company’s shares closed yesterday at $25.70, close to its 52-week high of $27.95.

Tanner observed:

“Quick take on the numbers ahead of conference call. SUPN released 4Q16/2016 results on February 28 and will host a conference call March 1 to discuss the results (9:00am EDT, 877-288-1043, #70744734). Changes to the model. We are decreasing our growth assumptions for Trokendi XR and Oxtellar XR, in keeping with SUPN guidance for 2017 net product revenue of $265-275 million, and increasing our G&A assumption to reflect operating income guidance of $75-80 million.”

According to, Tanner is a 3-star analyst with an average return of 5.2% and a 53.4% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Aquinox Pharmaceuticals, and Amag Pharmaceuticals.

Supernus Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $31.

The company has a one year high of $27.95 and a one year low of $12.15. Currently, Supernus Pharmaceuticals has an average volume of 459.2K.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is negative on the stock. Most recently, in December 2015, James Barrett, a Director at SUPN sold 212,970 shares for a total of $3,098,686.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Supernus Pharmaceuticals, Inc. develops and commercializes products for the treatment of central nervous system. It also develops multiple product candidates in psychiatry to address the large market opportunity in the treatment of attention deficit hyperactivity disorder, or ADHD, including ADHD patients with impulsive aggression. The company markets their products in the U.S. through their own focused sales force targeting specialty physicians and seek strategic collaborations with other pharmaceutical companies to license their products outside the U.S. Its neurology portfolio consists of Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended release topiramate). The company’s psychiatry product candidates include SPN-810 (molindone hydrochloride), SPN-812 and SPN-809. Supernus Pharmaceuticals was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.